1)Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92 : 205-216, 2000
2)Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours : revised RECIST guideline(version 1.1). Eur J Cancer 45 : 228-247, 2009
3)Koizumi W, Kurihara M, Tanabe S, et al. Advantages of Japanese response criteria for estimating the survival of patients with primary gastric cancer. Gastric Cancer 2 : 14-19, 1999
4)Kiyohashi A, Kurihara M, Yoshida S, et al. Antitumor effect and survival benefit of chemotherapy for unresectable advanced gastric cancer. Jpn J Clin Oncol 23 : 41-45, 1993
5)Ohtsu A, Boku N, Yoshida S, et al. Response of the primary lesion in gastric cancer to chemotherapeutic trials. Int J Clin Oncol 3 : 3-6, 1998
6)Yoshida S, Miyata Y, Ohtsu A, et al. Significance of and problems in adopting response evaluation criteria in solid tumor RECIST for assessing anticancer effects of advanced gastric cancer. Gastric Cancer 3 : 128-133, 2000
7)日本胃癌学会(編).胃癌取扱い規約,13版.pp18-21,金原出版,1999
8)日本食道学会(編).臨床・病理食道癌取扱い規約,10版補訂版.pp101-108,金原出版,2008
9)Tahara M, Ohtsu A, Hironaka S, et al. Clinical impact of criteria for complete response(CR)of primary site to treatment of esophageal cancer. Jpn J Clin Oncol 35 : 316-323, 2005
10)大腸癌研究会(編).大腸癌取扱い規約,6版.pp44-51,金原出版,1998
11)中谷研斗,樋口勝彦,小泉和三郎,他.RECIST─ガイドラインの適用と問題点 : 胃癌化学療法における原発巣評価の意義.日癌治療会誌 40 : 262, 2005
12)Park SR, Choi IJ, Kim CG, et al. Use of a combination of computed tomography and endoscopy to assess the response to 5-fluorouracil/cisplatin and predict survival in gastric cancer. J Gastroenterol 41 : 339-346, 2006